(243 days)
This device is intended to provide a means for sampling end tidal carbon dioxide with the option to deliver supplemental O2 therapy to patients for up to 24 hours.
Southmedic's CO2/02 Nasal Cannula incorporates sampling nares that channel expired carbon dioxide to a capnograph. A port located between the two nares is used to deliver oxygen to the patient as needed from an oxygen source. Its unique design delivers 02 to both the nose and mouth area. This device when in use involves surface contact to the patient's intact skin. There is also gas pathway contact between patient and tubing/nasal cannula. Contact is considered limited exposure (up to 24 hours).
The provided text describes several studies conducted to support the substantial equivalence of the Southmedic CO2/O2 Nasal Cannula. The studies focus on biocompatibility and performance.
1. Table of Acceptance Criteria and Reported Device Performance
| Test/Study Attribute | Acceptance Criteria | Reported Device Performance |
|---|---|---|
| Biocompatibility - Cytotoxicity (Agar Overlay) | The United States Pharmacopeia & National Formulary (USP 87) states that the test article meets criteria if the reactivity grade is not greater than 2 or a mild reactivity. The ANSI/AAMI/ISO 10993-5 standard states the achievement of a numerical grade greater than 2 is considered a cytotoxic effect. | Three samples were investigated obtaining an average score of 1. Results were compared to both positive and negative controls (average scores of 4 and 0 respectively). Conclusion: Southmedic's CO2/O2 Nasal Cannula is composed of materials that do not have a cytotoxic effect. |
| Biocompatibility - Sensitization (Guinea Pig Buehler) | Test results were based on incidence and severity of the sensitization reaction. Incidence was defined as the percentage of animals exhibiting a sensitization reaction at each observation time point (24 and 48 hours) post challenge. Severity was calculated by dividing the sum of the scores of one (1) or greater in the test group generally indicated sensitization, provided grades of less than one (1) were observed in the control animals. If severity of one (1) or greater was noted on the controls, then the reaction of the test animals exceeded the most severe control reaction to be considered due to sensitization. In the final analysis of data consideration was given to overall patterns, intensity, duration and character of reactions of the test as compared to the control animal. | No sensitization reaction was observed in either the control or test group. Conclusion: Southmedic's CO2/O2 Nasal Cannula is composed of materials that do not have a sensitization effect. |
| Biocompatibility - Primary Skin Irritation (Rabbits) | After the 72 hour scoring, all erythema plus edema scores generated during the 24±2, 48±2, and 72±2 hour observations were totaled separately for each test sample and control for each animal. The resulting totals for each animal were divided by 6 (two tests/observation site, three time points) to determine separate test article and control primary irritation scores for each animal. The primary irritation index is characterized by the number (score) and description (response category) given: - Negligible: >0 to 0.4 - Slight: 0.5 to 1.9 - Moderate: 2 to 4.9 - Severe: 5 to 8 | The test subject received a Primary Irritation Index Score of 0 in all areas. Conclusion: Since no skin irritation was observed in the test subjects, this test demonstrates that Southmedic's CO2/O2 Nasal Cannula is composed of materials that are a non-irritant to skin. |
| Performance - End Tidal CO2 Measurement | End tidal CO2 values for Southmedic Nasal Cannula shall not be statistically different, or shall vary less from the true end tidal CO2 value than the predicate products. | The end-tidal CO2 values for the Southmedic CO2/O2 Nasal Cannula was not statistically different, or varied less from the true end tidal CO2 value than predicate products. A comparison of variances of the end tidal CO2 measurements from the actual value for all four devices indicates that the Southmedic nasal cannula has the least variance from true value when compared to the three predicate devices within 95% confidence intervals. Conclusion: The Southmedic CO2/O2 Nasal Cannula met the predetermined acceptance criteria of the test and performs equally to, or better than, the predicate devices. |
2. Sample Size Used for the Test Set and Data Provenance
-
Biocompatibility Studies (Cytotoxicity, Sensitization, Irritation):
- Cytotoxicity: Three samples of the Southmedic device were tested. Control samples (positive and negative) were also used.
- Sensitization (Guinea Pig Buehler): Involved Guinea Pigs (number not explicitly stated, but implied to be sufficient for control and test groups). Data provenance is from Nelson Labs (an independent laboratory).
- Irritation (Rabbits): Involved Rabbits (number not explicitly stated, but implied to be sufficient for control and test subjects). Data provenance is from Nelson Labs (an independent laboratory).
- Provenance: All biocompatibility testing was "contracted to an independent laboratory" (Nelson Labs). The nature of these tests (animal models) implies prospective testing under controlled lab conditions.
-
Performance Study (End Tidal CO2 Measurement):
- Test Subjects: Southmedic's CO2/O2 Nasal Cannula and three predicate devices (Salter Labs #4706, Hudson RCI BiFlow 1850, UnoMedical/Hospitak 368E).
- Sample Size: "4 samples x 4 tests per sample x 3 respiratory settings x 4 oxygen flow rate settings = 144 tests total." This refers to testing configurations rather than biological subjects.
- Provenance: "comparative performance bench test against predicate devices was contracted from an independent laboratory" (Piper Laboratory). This is a prospective bench study using a "Harvard Respiratory pump and mannequin head to simulate patient conditions."
3. Number of Experts and Qualifications for Ground Truth
- Biocompatibility Studies: The ground truth for these studies (e.g., cytotoxicity score, presence/absence of sensitization, irritation index) is established by the methods and observations of the independent laboratory (Nelson Labs) performing the tests according to recognized standards (USP 87, ANSI/AAMI/ISO 10993-5, ISO 10993 Part 10). The qualifications of the personnel performing these lab tests are implied by their adherence to these standards, but specific expert qualifications (e.g., 'toxicologist with 10 years of experience') are not provided.
- Performance Study: The "true end tidal CO2 value" in the performance study refers to the simulated CO2 value set by the test apparatus with the Harvard Respiratory pump. The accuracy of measurements against this simulated "true value" is the ground truth. There is no mention of human experts establishing this ground truth, rather it's based on the controlled parameters of the simulation.
4. Adjudication Method for the Test Set
- Biocompatibility Studies: The adjudication method for these studies involves direct measurement and assessment of biological reactions (scores for cytotoxicity, observation for sensitization, irritation index calculation) as per the specified ISO and USP standards. This typically involves trained lab personnel following standardized protocols, not necessarily an "adjudication panel" in the clinical sense.
- Performance Study: The performance study measured end-tidal CO2 values against a simulated "true" value. There is no mention of an adjudication method involving experts for this test. The statistical analysis of the variance of measurements directly against the known simulated value served as the comparison.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study
No MRMC comparative effectiveness study was done. The device is a nasal cannula, and the studies performed are bench and biocompatibility tests, not clinical or diagnostic interpretation studies involving human readers.
6. Standalone (Algorithm Only Without Human-in-the-Loop Performance) Study
The device (CO2/O2 Nasal Cannula) is a physical medical device, not an algorithm or AI system. Therefore, the concept of a "standalone (algorithm only without human-in-the-loop performance)" study is not applicable. The performance study evaluates the physical device's ability to accurately sample CO2 and deliver O2 under simulated conditions.
7. Type of Ground Truth Used
- Biocompatibility Studies: Ground truth is based on standardized biological assays (e.g., cell culture reactions for cytotoxicity, animal responses for sensitization and irritation) interpreted against established regulatory and scientific criteria (USP, ISO standards).
- Performance Study: Ground truth is based on controlled simulated conditions using a mechanical respiratory pump and a mannequin head, where the "true end tidal CO2 value" is a predefined parameter of the simulation.
8. Sample Size for the Training Set
The concept of a "training set" is not applicable as this is a physical medical device and not an AI/ML model for which data models are trained. The studies described are for verification and validation of the device's physical properties and performance.
9. How the Ground Truth for the Training Set Was Established
Not applicable, as there is no training set for an AI/ML model.
{0}------------------------------------------------
KI31410
JAN 1 3 2014
510(k) Summary
| Date: | January 8, 2014 |
|---|---|
| Trade Name: | CO2/O2 Nasal Cannula |
| Common Name: | Oxygen Delivery, Carbon Dioxide Sampling Nasal Cannula |
| Classification Name: | Carbon Dioxide Gas Analyzer |
| Regulation: | Class II per 21CFR 868.1400 |
| Product Code: | CCK |
| Sponsor: | Southmedic Inc. |
| 50 Alliance Blvd. | |
| Barrie, ON | |
| L4M 5K3 | |
| Canada | |
| (705) 720-1902 | |
| Contact: | Tish Anger |
| Phone: | (705)720-1902 |
| Fax: | (705)728-9537 |
LEAGALLY MARKETED PREDICATE DEVICES
This premarket notification will demonstrate that Southmedic's CO2/02 Sampling Nasal Cannula is substantially equivalent to the devices listed below:
- . Salter Labs #4706 CO2/O2 Nasal Cannula (K892406)
- . Hudson RCI BiFlow 1850 (K961150)
- . UnoMedical/Hospitak 368E (K915228)
DEVICE DESCRIPTION
Southmedic's CO2/02 Nasal Cannula incorporates sampling nares that channel expired carbon dioxide to a capnograph. A port located between the two nares is used to deliver oxygen to the patient as needed from an oxygen source. Its unique design delivers 02 to both the nose and mouth area. This device when in use involves surface contact to the patient's intact skin. There
{1}------------------------------------------------
is also gas pathway contact between patient and tubing/nasal cannula. Contact is considered limited exposure (up to 24 hours).
INTENDED USE
This device is intended to provide a means for sampling end tidal carbon dioxide with the option to deliver supplemental O2 therapy to patients for up to 24 hours.
TECHNOLOGICAL CHARACTERISTICS
Southmedic's CO2/O2 Nasal Cannula and the predicate devices have similar technological characteristics. Specifically Southmedic's CO2/O2 Nasal Cannula and the predicate devices are all designed to draw expired end-tidal CO2 from the patient through the nasal cannula and tubing to a capnograph, and administer medical grade USP O2 to patients from an oxygen supply.
Southmedic's CO2/O2 Nasal Cannula's cannula has been designed with slight differences from the predicate devices. All predicate cannulae have two separate systems built into the part to allow for the delivery of oxygen and sampling of end-tidal carbon dioxide. Each predicate takes a different approach. Exhaled carbon dioxide is collected through the nasal prongs and a single port was created central to the nasal prongs for O2 delivery in Southmedic's model. Modification to the outer portion helps direct O2 down towards the mouth as well as the nose.
| Characteristic | Southmedic's CO2Sampling NasalCannula | Salter Labs#4706CO2/O2NasalCannula | Hudson RCIBiFlow 1850 | UnoMedical/Hospitak368E |
|---|---|---|---|---|
| 510(k) | K131410 | K892406 | K961150 | K915228 |
| Intended Use | This device is intendedto provide a means forsampling ETCO2 withthe option to deliversupplemental O2therapy to patients. | Same | Same | Same |
| Prescription | Yes | Yes | Yes | Yes |
| TechnologicalCharacteristics | Provides a means todeliver exhaled CO2 toa capnograph via | Same | Same | Same |
| Characteristic | Southmedic's CO2Sampling NasalCannula | Salter Labs#4706CO2/O2NasalCannula | Hudson RCIBiFlow 1850 | UnoMedical/Hospitak368E |
| Design | Collects CO2 fromnasal prongs anddelivers O2 though asingle port betweennasal prongs | Deliversoxygen fromone nasalprong andsamples CO2from the other. | Deliversoxygen andsamples CO2from bothnasal prongs. | Same as Southmedic's,however, O2 deliverythrough two portsrather than one. |
| Material | Phthalate free PVCNot made with naturalrubber latex. | PVCcontainingPhthalatesNot made withnatural rubberlatex. | PVCcontainingPhthalatesNot madewith naturalrubber latex. | PVC containingPhthalatesNot made with naturalrubber latex. |
| Energy Usedor Delivered | Not Applicable | Not Applicable | NotApplicable | Not Applicable |
| ManufacturingProcess | Injection molding,extrusion, assembly | Injectionmolding,extrusion,assembly | Injectionmolding,extrusion,assembly | Injection molding,extrusion, assembly |
| Performance | Same | Same | Same | Same |
| Labelling | Same | Same | Same | Same |
SUBSTANTIAL EQUIVALENCE SUMMARY
{2}------------------------------------------------
{3}------------------------------------------------
TESTING
In order to support the specific safety of Southmedic's CO2/02 Nasal Cannula, as well as confirm the suitability of the materials used in the manufacture of this product, extensive biocompatibility studies were contracted to an independent laboratory. The following table summarizes the biocompatibility testing conducted by Nelson Labs:
| Biocompatibility Testing | |
|---|---|
| Test/Method: | Agar Overlay -- Test for Cytotoxicity |
| Objective: | To determine the cytotoxicity of diffusible components frommaterials. |
| Acceptance Criteria | The United States Pharmacopeia & National Formulary (USP 87)states that the test article meets criteria if the reactivity grade is notgreater than 2 or a mild reactivity. The ANSI/AAMI/ISO 10993-5standard states the achievement of a numerical grade greater than 2 isconsidered a cytotoxic effect. |
| Results: | Three samples were investigated obtaining an average score of 1.Results were compared to both positive and negative controls(average scores of 4 and 0 respectively). |
| Discussion: | Southmedic's CO2/O2 Nasal Cannula is composed of materials thatdo not have a cytotoxic effect. This supports the safety of the deviceas well as the suitability of the materials used in its production. |
| Test/Method: | ISO 10993 Part 10 Guinea Pig Buehler Sensitization Test |
| Acceptance/EvaluationCriteria | Test results were based on incidence and severity of the sensitizationreaction. Incidence was defined as the percentage of animalsexhibiting a sensitization reaction at each observation time point (24and 48 hours) post challenge. Severity was calculated by dividing thesum of the scores of one (1) or greater in the test group generallyindicated sensitization, provided grades of less than one ( 1 ) wereobserved in the control animals. If severity of one (1) or greater wasnoted on the controls, then the reaction of the test animals exceededthe most severe control reaction to be considered due to sensitization.In the final analysis of data consideration was given to overallpatterns, intensity, duration and character of reactions of the test ascompared to the control animal. |
| Results: | No sensitization reaction was observed in either the control or testgroup. |
| Discussion | Southmedic's CO2/O2 Nasal Cannula is composed of materials thatdo not have a sensitization effect. This supports the safety of thedevice as well as the suitability of the materials used in its production. |
{4}------------------------------------------------
| Test/Method: | ISO 10993 Part 10 - Primary Skin Irritation Test in Rabbits | ||
|---|---|---|---|
| Acceptance/Evaluation Criteria: | After the 72 hour scoring, all erythema plus edema scores generated during the 24±2, 48±2, and 72±2 hour observations were totaled separately for each test sample and control for each animal. The resulting totals for each animal were divided by 6 (two tests/observation site, three time points) to determine separate test article and control primary irritation scores for each animal. The primary irritation index is characterized by the number (score) and description (response category) given in below: | ||
| Response Category | Primary Irritation Index (PII) | ||
| Negligible | >0 to 0.4 | ||
| Slight | 0.5 to 1.9 | ||
| Moderate | 2 to 4.9 | ||
| Severe | 5 to 8 | ||
| Results: | The test subject received a Primary Irritation Index Score of 0 in all areas. | ||
| Discussion: | Since no skin irritation was observed in the test subjects, this test demonstrates that Southmedic's CO2/O2 Nasal Cannula is composed of materials that are a non-irritant to skin. This supports the safety of the device as well as the suitability of the materials used in its production. |
Risk evaluation performed by Southmedic determined that because of the well characterized safe and effective use of nasal cannulas for oxygen delivery and end tidal CO2 sampling, animal or clinical testing were not necessary to support this application. In order to confirm effectiveness of Southmedic's CO2/O2 Nasal Cannula for its intended use, a comparative performance bench test against predicate devices was contracted from an independent laboratory. The following table summarizes the performance testing conducted by Piper Laboratory:
| Study Attribute | Description |
|---|---|
| Test subjects | Southmedic's CO2/O2 Nasal Cannula was tested and results comparedagainst predicate devices (see above) |
| Objective | To measure the end tidal CO2 values of four oxygen delivering nasalcannulae under simulated patient conditions |
| Acceptance Criteria | End tidal CO2 values for Southmedic Nasal Cannula shall not bestatistically different, or shall vary less from the true end tidal CO2value than the predicate products |
| Apparatus | Harvard Respiratory pump and mannequin head to simulate patienthead. Nasal cannula connected to oxygen supply line, CO2 sensingline and CO2 detector (capnograph) |
{5}------------------------------------------------
| SimulatedRespiratory Settings | 1. Adult, Respiratory Rate 8, Tidal Volume 8002. Adult, Respiratory Rate 16, Tidal Volume 6003. Pediatric, Respiratory Rate 30, Tidal Volume 300All conditions had I:E ratio of 1:1 (inspiration:expiration) |
|---|---|
| Deviations | No deviations were noted during the study. All equipment metpredetermined operation and calibration testing before and after testing |
| Oxygen delivery forstudy | Source flows of 0, 1, 3, and 5 liters per minute for each setting wasused. The system was allowed at least 3 minutes with oxygen deliverprior to sampling CO2 to allow the system to equilibrate. |
| Measurements | Each test was sampled three times at each combination of settings for atotal of 144 tests ( 4 samples x 4 tests per sample x 3 respiratorysettings x 4 oxygen flow rate settings = 144 tests total) |
| Results | The end-tidal CO2 values for the Southmedic CO2/O2 Nasal Cannulawas not statistically different, or varied less from the true end tidalCO2 value than predicate products.A comparison of variances of the end tidal CO2 measurements fromthe actual value for all four devices indicates that the Southmedic nasalcannula has the least variance from true value when compared to thethree predicate devices within 95% confidence intervals. |
| Discussion | The Southmedic CO2/O2 Nasal Cannula met the predeterminedacceptance criteria of the test.Both Southmedic's CO2/O2 Nasal Cannula and predicate devices areintended to provide a means for sampling ETCO2 with the option todeliver supplemental O2 therapy to patients. This performance testdemonstrated that Southmedic's CO2/O2 Nasal Cannula performsequally to, or better than, the predicate devices in measuring end tidalCO2. This supports the substantial equivalence of Southmedic'sCO2/O2 Nasal Cannula to the predicate products. |
CONCLUSIONS
In summary, Southmedic's CO2/O2 Nasal Cannula path through the 510(k) regulatory analysis is as follows:
- . The Southmedic CO2/02 Nasal Cannula and the predicate devices are all intended for use as a means for sampling ETCO2 with the option to deliver supplemental O2 therapy to patients.
- The Southmedic CO2/O2 Nasal Cannula has similar key technological characteristics as . the predicate devices. All three are manufactured by extrusion, injection molding, and assembly. Designs are based on the same principle of one tube providing oxygen from a source and the other delivering expired CO2 to a capnograph.
- In order to verify the safety of the materials used in the manufacture of Southmedic's . CO2/02 Nasal Cannula, extensive biocompatibility testing was conducted. The testing demonstrated that materials used have no cytotoxic effect. The testing also confirmed
б
{6}------------------------------------------------
that the materials used are a non-irritant and do not have a sensitization effect. These results help support the safety of Southmedic's CO2/O2 Nasal Cannula
- . The use of nasal cannulas for sampling CO2 and delivering oxygen is well established in the medical community. In order to address any difference between Southmedic's CO2/02 Nasal Cannula and the predicate devices in their design, additional studies were performed. In order to demonstrate the effectiveness of the new design, a comparative bench test was conducted on Southmedic's behalf. The results demonstrated that Southmedic's CO2/02 Nasal Cannula varied less or equal to the true values when compared to the predicate device. This supports the effectiveness of the device.
Therefore, Southmedic's CO2/02 Nasal Cannula meets the criteria for substantial equivalence to Salter Lab's CO2/O2 Nasal Cannula, Hudson RCI Biflow Cannula, and the UnoMedical/Hospitak Nasal Cannula.
{7}------------------------------------------------
Image /page/7/Picture/1 description: The image shows the seal of the Department of Health & Human Services - USA. The seal is circular, with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" written around the perimeter. In the center of the seal is an abstract image of an eagle.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
January 13, 2014
Southmedic Incorporated Ms. Tish Anger Vice President of Quality and Regulatory Assurance 50 Alliance Blvd. Barrie, Ontario Canada L4M 5K3
Re: K131410
Trade/Device Name: CO2/02 Nasal Cannula Regulation Number: 21 CFR 868.1400 Regulation Name: Carbon Dioxide Gas Analyzer Regulatory Class: II Product Code: CCK Dated: December 12, 2013 Received: December 13, 2013
Dear Ms. Anger:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{8}------------------------------------------------
Page 2 - Ms. Anger
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely vours.
FOR
Erin I. Keith, M.S. Acting Director Division of Anesthesiology, General Hospital, Respiratory, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{9}------------------------------------------------
Indications for Use
CO2/O2 Nasal Cannula
510(k) Number:
Device Name:
Intended Use:
This device is intended to provide a means for sampling end tidal carbon dioxide with the option to deliver supplemental O2 therapy to patients for up to 24 hours.
Prescription Use_ X (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
Concurrence of CDRH, Office of Device Evaluation (ODE)
-05'00'
Page 1 of 1
Page 11
§ 868.1400 Carbon dioxide gas analyzer.
(a)
Identification. A carbon dioxide gas analyzer is a device intended to measure the concentration of carbon dioxide in a gas mixture to aid in determining the patient's ventilatory, circulatory, and metabolic status. The device may use techniques such as chemical titration, absorption of infrared radiation, gas chromatography, or mass spectrometry.(b)
Classification. Class II (performance standards).